Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,772 signal articles · 79 in last 24h · 148,324 total before filter · latest 37m ago
79last 24h
979last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
AllMacro369Earnings115M&A99Regulatory8Product11Analyst12
✕ clear all filtersticker: AMGNSentiment:bullishneutralbearishshow all (incl. clickbait)
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
24/7 Wall St.9d agoneutral
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More

Pre-Market Stock Futures: Futures are trading mixed after a second brutal day, with all major indices finishing lower again. Rising rates, Brent Crude trading above $100, and what appears to be an increase in the Iran attacks in the Persian Gulf were all it took for sellers to keep hitting bids. Once again, the small-cap […]

Jobs Numbers, SpaceX Earnings: What to Watch This Week
The Wall Street Journal47d agoneutral
Jobs Numbers, SpaceX Earnings: What to Watch This Week

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
Reuters79d agoneutral
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move ‌by a U. In granting a preliminary injunction, Chief Judge Daniel Domenico ‌of the Denver federal court said Amgen would likely face significant and irreparable harm from charging lower prices, ​adding that it could affect the drugmaker's negotiations for future contracts with wholesalers and distributors.